Illustrative concept image.
Purpose & realistic expectations
Semaglutide acts at GLP-1 receptors and tirzepatide at GIP and GLP-1 receptors. They are examples for discussion. Egyptian registration, exact indication, availability and the current product label must be verified by the prescribing clinician.
Assessment & planning
A clinician reviews your history and current treatment before recommending a pathway. Testing is based on clinical need. Practical goals are agreed around your health and routine, with follow-up adapted to your response.
Precautions & limitations
Review includes pregnancy plans, pancreatitis or gallbladder history, gastrointestinal symptoms, medicines and product-specific contraindications such as MTC or MEN2 where labelled. Nausea, vomiting, dehydration and other adverse effects require monitoring. This website provides no prescription or automatic eligibility decision.
Availability & next steps
REVIVE is preparing for launch in New Cairo. Service availability, the responsible professionals and applicable approvals must be confirmed before any appointment or procedure. An inquiry is not an appointment confirmation.
Frequently asked questions
Is this available now?
REVIVE is preparing for launch in New Cairo. Service availability, the responsible professionals and applicable approvals must be confirmed before any appointment or procedure. An inquiry is not an appointment confirmation.
How is suitability decided?
A clinician reviews your history and current treatment before recommending a pathway. Testing is based on clinical need. Practical goals are agreed around your health and routine, with follow-up adapted to your response.
References & further reading
NIDDK — Prescription medicines for overweight and obesityContent prepared 15 November 2026. Formal medical review pending. No reviewer or approval is implied. This information supports, and does not replace, an individualized clinical consultation.